Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot improve natural lubrication?
The O-Shot may support natural lubrication for selected patients where local tissue quality, arousal response, blood flow, and low-oestrogen change are part of the picture. It cannot promise a predictable lubrication response.
Direct answer
The O-Shot may support natural lubrication for selected patients where local tissue quality, arousal response, blood flow, and low-oestrogen change are part of the picture. It cannot promise a predictable lubrication response.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
Mechanism
Harvests powerful growth factors (such as VEGF and PDGF) from a patient's blood to trigger tissue regeneration.
Benefits
Patients commonly report increased natural lubrication, reduced vaginal dryness, heightened sexual sensitivity, stronger orgasms, and relief from mild.
Target Audience
Ideal for women experiencing Genitourinary Syndrome of Menopause (GSM), postpartum changes, dyspareunia (painful sex), or those who prefer.
Efficacy
Systematic reviews indicate that improvements in vaginal lubrication can range from 20% to 60% from baseline.
Important safety note
Safety Profile: The procedure is considered very low-risk because it uses an autologous biologic (the patient's own blood), virtually eliminating the risk of allergic or immune reactions.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
Regulatory Status: The use of PRP for vaginal atrophy and sexual dysfunction is currently considered an "off-label" use of the technology and is not specifically FDA-approved for these indications.
Clinical context
Regulatory Status: The use of PRP for vaginal atrophy and sexual dysfunction is currently considered an "off-label" use of the technology and is not specifically FDA-approved for these.
Evidence
Symptoms
Alternatives
What it means
Regulatory Status: The use of PRP for vaginal atrophy and sexual dysfunction is currently considered an "off-label" use of the technology and is not specifically FDA-approved for these.
Why it happens
Clinical Trials: A 2026 randomised controlled trial (RCT) found a statistically significant improvement in total Female Sexual Function Index (FSFI) scores at 6 weeks and 6 months.
Evidence limits
Variable Outcomes: Some studies, such as a recent trial comparing PRP to topical oestrogen, showed reported improvements in dyspareunia (painful sex) but no statistically significant difference in dryness.
Treatment fit
Standardisation Needs: While clinical evidence is promising, the medical community emphasises the need for more large-scale RCTs to standardise PRP preparation protocols, injection depths, and dosages.
What this means in practice
Time Commitment: The entire appointment is brief, typically taking 30 to 45 minutes from door to door, with the actual injection taking only 5 to 10 minutes. Cost: As an elective, off-label procedure, it is generally not covered by health insurance.
Initial Response: Some patients report noticing an immediate increase in sensation and moisture, though heightened sensitivity and early tissue changes typically begin 3 to 7 days or 2 to 6 weeks post-treatment.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
Regulatory Status: The use of PRP for vaginal atrophy and sexual dysfunction is currently considered an "off-label" use of the technology and is not specifically FDA-approved for these.
It protects safety
Safety Profile: The procedure is considered very low-risk because it uses an autologous biologic (the patient's own blood), virtually eliminating the risk of allergic or immune reactions.
It reviews alternatives
Time Commitment: The entire appointment is brief, typically taking 30 to 45 minutes from door to door, with the actual injection taking only 5 to 10 minutes.
It sets expectations
Initial Response: Some patients report noticing an immediate increase in sensation and moisture, though heightened sensitivity and early tissue changes typically begin 3 to 7 days or 2.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Time Commitment: The entire appointment is brief, typically taking 30 to 45 minutes from door to door, with the actual injection taking only 5 to 10 minutes. Cost: As an elective, off-label procedure, it is generally not covered by health insurance.
Consultation priorities
Consultation: The process begins with a thorough evaluation of the patient's medical history, sexual health goals, and symptoms to ensure candidate suitability.
Consent
Aftercare
Follow-up
Before treatment
Consultation: The process begins with a thorough evaluation of the patient's medical history, sexual health goals, and symptoms to ensure candidate suitability.
During care
Preparation: A topical numbing cream (often a highly concentrated BLT compound) is applied to the clitoris and vaginal wall for 15-20 minutes to ensure a painless experience.
Aftercare
The Injection: The provider uses ultra-fine needles to precisely inject the concentrated PRP. Most patients report feeling only mild pressure or a slight pinch.
When to reassess
Aftercare: Patients can resume normal daily activities immediately.
Practical expectations
Initial Response: Some patients report noticing an immediate increase in sensation and moisture, though heightened sensitivity and early tissue changes typically begin 3 to 7 days or 2.
Cost: As an elective, off-label procedure, it is generally not covered by health insurance.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Lubrication is only a physical problem.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: PRP creates the same response in every patient.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: More lubrication automatically means every part of sex improves.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Clinical Trials: A 2026 randomised controlled trial (RCT) found a statistically significant improvement in total Female Sexual Function Index (FSFI) scores at 6 weeks and 6 months.
Alternatives
Time Commitment: The entire appointment is brief, typically taking 30 to 45 minutes from door to door, with the actual injection taking only 5 to 10 minutes.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Safety Profile: The procedure is considered very low-risk because it uses an autologous biologic (the patient's own blood), virtually eliminating the risk of allergic or immune reactions.
Are alternatives clear?
Time Commitment: The entire appointment is brief, typically taking 30 to 45 minutes from door to door, with the actual injection taking only 5 to 10 minutes.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Safety Profile: The procedure is considered very low-risk because it uses an autologous biologic (the patient's own blood), virtually eliminating the risk of allergic or immune reactions.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Safety Profile: The procedure is considered very low-risk because it uses an autologous biologic (the patient's own blood), virtually eliminating the risk of allergic or immune reactions.
Bleeding or discharge
Common Side Effects: Minor, temporary effects may include brief spotting, mild swelling, redness, or a slight pinching sensation that usually resolves within 1 to 2 days.
Infection signs
Contraindications: The treatment is not suitable for women who are pregnant, have an active pelvic infection, suffer from blood-clotting or platelet disorders, or have a history of untreated.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The best page owns the distinction between lubrication, arousal, dryness, and pain, giving the reader a clinically literate way to understand her symptom.
Clinical reality
- Regulatory Status: The use of PRP for vaginal atrophy and sexual dysfunction is currently considered an "off-label" use of the technology and is not specifically FDA-approved for these indications.
- Clinical Trials: A 2026 randomised controlled trial (RCT) found a statistically significant improvement in total Female Sexual Function Index (FSFI) scores at 6 weeks and 6 months in the PRP group, though changes.
- Variable Outcomes: Some studies, such as a recent trial comparing PRP to topical oestrogen, showed reported improvements in dyspareunia (painful sex) but no statistically significant difference in dryness specifically.
- Standardisation Needs: While clinical evidence is promising, the medical community emphasises the need for more large-scale RCTs to standardise PRP preparation protocols, injection depths, and dosages.
Timeline and expectations
- Initial Response: Some patients report noticing an immediate increase in sensation and moisture, though heightened sensitivity and early tissue changes typically begin 3 to 7 days or 2 to 6 weeks post-treatment.
- Peak Results: Because the treatment relies on cellular regeneration and new tissue development, the full, optimal effects usually manifest around the 3-month mark.
- Duration: The rejuvenating effects are not expected to be indefinite; they generally last between 12 and 18 months, with some women experiencing benefits for up to 3 years.
- Maintenance: To sustain optimal lubrication and sexual function, patients often repeat the procedure annually or every 18 months.
Practical logistics
- Time Commitment: The entire appointment is brief, typically taking 30 to 45 minutes from door to door, with the actual injection taking only 5 to 10 minutes.
- Costs should be confirmed on the /pricing/ page before booking
- The Process: It involves a simple blood draw (10-20 mL), 10-15 minutes of centrifugation to isolate the PRP, and injection into the anaesthetised clitoris and anterior vaginal wall.
Research sources
- Clarke et al. (2026), Obstetrics & gynaecology: "Vaginal Injection of Platelet-Rich Plasma for Sexual Function: A randomised Controlled Trial"
- Ismail et al. (2025), Revista Iberoamericana de Psicología del Ejercicio y el Deporte: "Role of Platelet-Rich Plasma in Female Sexual Health and Recovery: A Systematic Review"
- Atlihan et al. (2025), Frontiers in Medicine: "Comparison of topical oestrogen and platelet-rich plasma injections in the treatment of postmenopausal vaginal atrophy"
- De Ponte et al. (2026), Journal of Sexual Medicine: "Platelet-rich plasma in the management of vulvovaginal disorders: a systematic review"
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE interventional procedures guidance
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 135 imported records. Additional reviewed material included professional society guidance, peer-reviewed clinical papers, evidence reviews, clinical trial records; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. The information provided in this document is for educational and informational purposes only and does not constitute professional medical advice. While PRP therapy has early clinical evidence for improving natural lubrication and sexual function, the use of PRP for vaginal rejuvenation is considered an off-label procedure. Always consult with an appropriately qualified gynaecologist or urogynaecologist to properly diagnose symptoms, review potential risks, and determine the most appropriate treatment for your individual health profile. Results vary. Not a cure.
